Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechSci Research | PRODUCT CODE: 1886617

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1886617

Glaucoma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Glaucoma Type, By Region and Competition, 2020-2030F

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4500
PDF and Excel (Multi-User License)
USD 5500
PDF and Excel (Custom Research License)
USD 8000

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

The Global Glaucoma Therapeutics Market , valued at USD 7.33 Billion in 2024, is projected to experience a CAGR of 6.57% to reach USD 10.74 Billion by 2030. The global glaucoma therapeutics market encompasses pharmacological and surgical interventions designed to reduce intraocular pressure and prevent optic nerve damage, thereby preserving vision in individuals diagnosed with glaucoma. Key drivers supporting market growth include the rising global prevalence of glaucoma and the expanding geriatric population.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.33 Billion
Market Size 2030USD 10.74 Billion
CAGR 2025-20306.57%
Fastest Growing SegmentMedication
Largest MarketNorth America

Key Market Drivers

The increasing global geriatric population represents a fundamental demographic shift significantly influencing the glaucoma therapeutics market. As individuals age, their susceptibility to developing glaucoma rises substantially, making this demographic expansion a primary driver of increased patient volumes. Older age is a well-established risk factor for glaucoma onset and progression, directly translating to a greater need for diagnostic screenings and subsequent therapeutic interventions.

Key Market Challenges

Patient non-adherence to long-term medication regimens presents a substantial impediment to the expansion of the global glaucoma therapeutics market. The efficacy of pharmacological interventions for glaucoma is fundamentally dependent on consistent and timely patient compliance to effectively reduce intraocular pressure and avert progressive optic nerve damage. When individuals do not adhere to their prescribed treatment schedules, the disease often progresses unchecked, leading to a greater need for more advanced and often expensive surgical procedures or a shift to alternative, more complex drug therapies. This undermines the overall perceived value and effectiveness of current pharmaceutical offerings and disrupts the consistent demand for long-term medication supplies.

Key Market Trends

The integration of artificial intelligence in glaucoma diagnostics and management represents a transformative trend, enhancing the precision and efficiency of patient care. AI algorithms can analyze complex ophthalmic imaging and clinical data to facilitate earlier disease detection and more accurate progression monitoring, thereby enabling timely interventions.

Key Market Players

  • Novartis AG
  • Merck & Co., Inc.
  • AbbVie, Inc.
  • Bausch Health Companies, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Alcon, Inc.
  • Inotek Pharmaceuticals Corporation

Report Scope:

In this report, the Global Glaucoma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Glaucoma Therapeutics Market , By Treatment Type:

  • Eye drops
  • Medication
  • Laser Surgery
  • Traditional Surgery

Glaucoma Therapeutics Market , By Glaucoma Type:

  • Open angle
  • Closed angle

Glaucoma Therapeutics Market , By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Glaucoma Therapeutics Market .

Available Customizations:

Global Glaucoma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Product Code: 22729

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Glaucoma Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Eye drops, Medication, Laser Surgery, Traditional Surgery)
    • 5.2.2. By Glaucoma Type (Open angle, Closed angle)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Glaucoma Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Glaucoma Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Glaucoma Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Glaucoma Type
    • 6.3.2. Canada Glaucoma Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Glaucoma Type
    • 6.3.3. Mexico Glaucoma Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Glaucoma Type

7. Europe Glaucoma Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Glaucoma Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Glaucoma Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Glaucoma Type
    • 7.3.2. France Glaucoma Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Glaucoma Type
    • 7.3.3. United Kingdom Glaucoma Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Glaucoma Type
    • 7.3.4. Italy Glaucoma Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Glaucoma Type
    • 7.3.5. Spain Glaucoma Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Glaucoma Type

8. Asia Pacific Glaucoma Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Glaucoma Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Glaucoma Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Glaucoma Type
    • 8.3.2. India Glaucoma Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Glaucoma Type
    • 8.3.3. Japan Glaucoma Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Glaucoma Type
    • 8.3.4. South Korea Glaucoma Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Glaucoma Type
    • 8.3.5. Australia Glaucoma Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Glaucoma Type

9. Middle East & Africa Glaucoma Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Glaucoma Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Glaucoma Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Glaucoma Type
    • 9.3.2. UAE Glaucoma Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Glaucoma Type
    • 9.3.3. South Africa Glaucoma Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Glaucoma Type

10. South America Glaucoma Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Glaucoma Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Glaucoma Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Glaucoma Type
    • 10.3.2. Colombia Glaucoma Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Glaucoma Type
    • 10.3.3. Argentina Glaucoma Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Glaucoma Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Glaucoma Therapeutics Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. AbbVie, Inc.
  • 15.4. Bausch Health Companies, Inc.
  • 15.5. Teva Pharmaceutical Industries Ltd.
  • 15.6. Pfizer Inc.
  • 15.7. Alcon, Inc.
  • 15.8. Inotek Pharmaceuticals Corporation

16. Strategic Recommendations

17. About Us & Disclaimer

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!